-
Ugeskrift For Laeger Apr 2022
Topics: Humans; Organic Chemicals; Pyoderma; Skin Diseases, Bacterial
PubMed: 35485797
DOI: No ID Found -
Dermatologic Clinics Apr 2024The term neutrophilic dermatosis encompasses a heterogeneous group of diseases, often associated with an underlying internal noninfectious disease, with an overlapping... (Review)
Review
The term neutrophilic dermatosis encompasses a heterogeneous group of diseases, often associated with an underlying internal noninfectious disease, with an overlapping histopathologic background characterized by perivascular and diffuse neutrophilic infiltrates in one or more layers of the skin; extracutaneous neutrophilic infiltrates may be associated. Neutrophilic dermatoses are not frequent in children and, when they appear in this age group, represent a diagnostic and therapeutic challenge. Apart from the classic neutrophilic dermatoses such as pyoderma gangrenosum, Sweet syndrome, and Behçet disease, a neutrophilic dermatosis can be the presentation of rare genetic diseases of the innate immune system, such as autoinflammatory diseases.
Topics: Humans; Child; Dermatitis; Pyoderma Gangrenosum; Skin; Sweet Syndrome; Neutrophils
PubMed: 38423686
DOI: 10.1016/j.det.2023.12.005 -
The New England Journal of Medicine Nov 2022
Topics: Humans; Pyoderma Gangrenosum
PubMed: 36351270
DOI: 10.1056/NEJMicm2204111 -
The Journal of Dermatology Sep 2023Pyoderma gangrenosum (PG) is a rare, neutrophilic skin disease. For the purpose of accurate diagnosis and proper treatment of PG, the Japanese clinical practice guidance...
Pyoderma gangrenosum (PG) is a rare, neutrophilic skin disease. For the purpose of accurate diagnosis and proper treatment of PG, the Japanese clinical practice guidance for PG developed by the Japanese Dermatological Association was published in 2022. In this guidance, clinical aspects, pathogenesis, current therapies, and clinical questions on PG are described from the viewpoints of current knowledge and evidence-based medicine. Here, the English version of the Japanese clinical practice guidelines for PG is presented and is intended to be widely referred to in the clinical examination and treatment of PG.
Topics: Humans; Pyoderma Gangrenosum
PubMed: 37311717
DOI: 10.1111/1346-8138.16845 -
Nature Reviews. Disease Primers Oct 2020
Topics: Humans; Pyoderma Gangrenosum; Quality of Life
PubMed: 33033257
DOI: 10.1038/s41572-020-00221-6 -
Archives of Dermatological Research Aug 2019Pyoderma Gangrenosum (PG) is an inflammatory neutrophilic dermatosis (ND) associated with underlying chronic inflammation and/or malignancy. Diagnosis remains to be... (Review)
Review
Pyoderma Gangrenosum (PG) is an inflammatory neutrophilic dermatosis (ND) associated with underlying chronic inflammation and/or malignancy. Diagnosis remains to be challenging as a gold standard diagnostic test is lacking. Initial manifestations may include papules, vesicles, or pustules that subsequently develop into ulceration with features of undermining and violaceous borders. Timely recognition of pyoderma gangrenosum is impeded by clinical findings shared with other etiologies, such as granulomatosis with polyangiitis, polyarteritis nodosa, and antiphospholipid syndrome. As with any other ND, extracutaneous involvement may also occur preceding, during, or following the appearance of skin lesions. Sterile neutrophilic infiltrates have been found to affect internal organs supporting the concept of PG being a systemic disease, with lung being the most common extracutaneous manifestation followed by ocular and visceral compromise. Therefore, in this review, we describe the current knowledge of extracutaneous involvement of PG and its respective clinical manifestations to aid dermatologists in diagnosis, management, and determining prognosis.
Topics: Bone and Bones; Diagnosis, Differential; Eye; Humans; Kidney; Lung; Pyoderma Gangrenosum; Skin; Spleen; Sweet Syndrome
PubMed: 30923901
DOI: 10.1007/s00403-019-01912-1 -
Cirugia Espanola Oct 2021
Topics: Humans; Perineum; Pyoderma Gangrenosum
PubMed: 34305028
DOI: 10.1016/j.cireng.2021.07.002 -
Clinical Gastroenterology and... Jul 2019
Topics: Humans; Piperidines; Pyoderma Gangrenosum; Pyrimidines; Pyrroles
PubMed: 30625401
DOI: 10.1016/j.cgh.2018.12.044 -
Dermatology (Basel, Switzerland) 2022Pyoderma gangrenosum (PG) is a rare ulcerating skin disease associated with multiple comorbidities and increased mortality. In recent decades, newer biologics such as... (Review)
Review
BACKGROUND
Pyoderma gangrenosum (PG) is a rare ulcerating skin disease associated with multiple comorbidities and increased mortality. In recent decades, newer biologics such as interleukin inhibitors have been used to treat PG; however, the literature is scarce, consisting predominantly of case reports and caseseries. The aim of our review was to evaluate the effectiveness and safety of interleukin inhibitors for the treatment of PG in adults.
SUMMARY
A literature search was conducted using search terms related to PG and interleukin inhibitors in databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane Library. The study eligibility criteria included patients diagnosed with PG, over the age of 18, and treated with an interleukin inhibitor. Our study included 60 papers describing 81 patients fulfilling the eligibility criteria. The treatment with interleukin inhibitors resulted in 70% (95% CI 59-80%) response and 57% (95% CI 45-68%) complete response rates, and few (4%) mild adverse events, hence supporting the off-label use for the treatment of recalcitrant PG in adults. The response and complete response rates were 59% (17/29) and 38% (11/29) for anakinra, 64% (7/11) and 55% (6/11) for canakinumab, and 79% (27/34) and 71% (24/34) for ustekinumab, respectively. Limitations include publication bias that might have overestimated the efficacy as successful cases responding to treatment are more likely to be reported than nonresponding cases. Additionally, the heterogeneity of the treatment groups does not allow conclusions of superiority or inferiority of the different interleukin inhibitors to be drawn. Further studies are needed to investigate the efficacy of the different interleukin inhibitors and to investigate the importance of underlying disease for treatment response.
Topics: Adult; Biological Products; Humans; Interleukin Inhibitors; Middle Aged; Pyoderma Gangrenosum
PubMed: 34710873
DOI: 10.1159/000519320 -
Dermatologic Clinics Apr 2024Neutrophilic dermatoses (NDs) encompass a wide range of cutaneous and extracutaneous manifestations, many of which impair quality of life (QoL) and are difficult to... (Review)
Review
Neutrophilic dermatoses (NDs) encompass a wide range of cutaneous and extracutaneous manifestations, many of which impair quality of life (QoL) and are difficult to treat. Although NDs are transient and mild, others are chronic, severely debilitating conditions with profound impacts on QoL, including pain, mental health, occupational limitations, and sexual health implications. Current literature lacks attention to these unique care challenges to the ND patient population. The authors aim to summarize what is currently known about QoL in NDs and identify which diseases would benefit from additional research and disease-specific QoL assessment.
Topics: Humans; Pyoderma Gangrenosum; Quality of Life; Neutrophils; Skin; Sweet Syndrome
PubMed: 38423691
DOI: 10.1016/j.det.2023.08.011